Longeveron Inc. - Class A Common stock (NQ:LGVN)

1.670 -0.080 (-4.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Longeveron Inc. - Class A Common stock

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

APPROACHING DEADLINE REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Longeveron Inc. And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

November 03, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Initial Public Offering Lawsuit

SHAREHOLDER ALERT: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Longeveron Inc. (LGVN)

November 03, 2021

From Longeveron

Via Business Wire

The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline ↗

August 18, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)...

Via Benzinga

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business ↗

August 17, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...

Via Benzinga

5 Cheap Stocks Set to Double This Month ↗

November 02, 2021

This article is excerpted from Tom Yeung's Moonshot Investor newsletter. To make sure you don't miss any of Tom's potential 100x picks, subscribe to his

Via InvestorPlace

NASDAQ:LGVN Investor Notice: Deadline on November 12, 2021 in Lawsuit Against Longeveron Inc. ↗

October 27, 2021

San Diego, CA -- (SBWIRE) -- 10/27/2021 -- The Shareholders Foundation announced that a deadline is coming up on November 12, 2021 in the lawsuit filed for certain investors of Longeveron Inc....

Via SBWire

Topics Initial Public Offering Lawsuit

3 Penny Stocks Insiders Are Buying ↗

October 15, 2021

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider...

Via Benzinga

2 Penny Stocks Insiders Are Buying ↗

October 13, 2021

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...

Via Benzinga

ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Encourages Longeveron Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important November 12 Deadline in Securities Class Action – LGVN

October 09, 2021

From The Rosen Law Firm, P.A.

Via Business Wire

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results ↗

October 07, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

October 04, 2021

Gainers Longeveron (NASDAQ:LGVN) shares ...

Via Benzinga

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

October 04, 2021

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Initial Public Offering Lawsuit

Longeveron Successfully Advancing its Cell-Based Therapy Studies in a Growing Industry Segment ↗

October 04, 2021

Research and development of stem cell-based therapies, where a patient’s own cells, or those from a donor, are used to fight injury and disease, is one of the fastest...

Via Benzinga

Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity ↗

September 29, 2021

Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent decrease in Tie-2 at Day 270 Oral...

Via Benzinga

NASDAQ:LGVN Investor Notice: Lawsuit Alleges Securities Laws Violations by Longeveron Inc. ↗

September 29, 2021

San Diego, CA -- (SBWIRE) -- 09/29/2021 -- An investor, who purchased shares of Longeveron Inc. (NASDAQ:LGVN), filed a lawsuit over alleged violations of Federal Securities Laws by Longeveron Inc. in...

Via SBWire

Topics Initial Public Offering Lawsuit Regulatory Compliance

EXCLUSIVE: Longeveron Announces Biomarker Analysis Data From Mid-Stage Study Of Anti-Aging Cell Therapy Candidate ↗

September 29, 2021

Longeveron Inc. (NASDAQ: LGVN) announced Wednesday positive biomarker analysis data from the mid-stage study of its lead cell therapy candidate in aging frailty subjects. What...

Via Benzinga

LONGEVERON ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Longeveron Inc. and Encourages Investors to Contact the Firm

September 17, 2021

From Bragar Eagel & Squire, P.C.

Via Business Wire

SHAREHOLDER ALERT: Robbins LLP Announces that Longeveron Inc. (LGVN) is Being Sued for Misleading Shareholders

September 17, 2021

From Robbins LLP

Via Business Wire

Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveron ↗

September 15, 2021

Photo by jesse orrico on Unsplash Researchers in the medical field are constantly working to create medicines to prevent and cure diseases. The development of the multiple COVID-...

Via Benzinga

SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

September 15, 2021

From The Schall Law Firm

Via Business Wire

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Longeveron Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

September 14, 2021

From The Schall Law Firm

Via Business Wire

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Longeveron Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – LGVN

September 14, 2021

From Rosen Law Firm

Via Business Wire

Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients ↗

September 09, 2021

--Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment. --Secondary...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 09, 2021

Gainers Soligenix (NASDAQ:SNGX) stock increased by 22.85% to $1.29 during Thursday's pre-market session. The company's market cap stands at $51.7 million. Cardiff...

Via Benzinga

EXCLUSIVE: Longeveron's Lomecel-B Cell Therapy Meets Primary Safety Endpoint In Phase 1 Rare Congenital Heart Disease Study ↗

September 09, 2021

Longeveron Inc. (NASDAQ: LGVN), a cell therapy company developing therapies for age-related and life-threatening conditions, reported Thursday final results from a Phase 1 study...

Via Benzinga

NASDAQ:LGVN Investor Notice: Investigation over Possible Securities Laws Violations by Longeveron Inc. ↗

September 02, 2021

San Diego, CA -- (SBWIRE) -- 09/02/2021 -- Longeveron Inc is under investigation over potential securities laws violations in connection with certain financial statements.

Via SBWire

38 Stocks Moving In Monday's Mid-Day Session ↗

August 16, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares climbed 34.5% to $3.3900 after the company announced plan to expand product portfolio with introduction of Painshield relief for...

Via Benzinga

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal ↗

August 24, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 23) AbbVie Inc. (NYSE: ABBV) (...

Via Benzinga

60 Biggest Movers From Yesterday ↗

August 17, 2021

Gainers NanoVibronix, Inc. (NASDAQ: NAOV) shares jumped 33.7% to close at $3.37 on Monday after the company announced plan to expand product portfolio with introduction of...

Via Benzinga

< Previous 1 2

...

10 11 12 13 14 15 16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.